AstraZeneca has released a statement saying its vaccine is safe and effective. Over 32,000 participants in the US are on phase 3 of a trial. The company boasted in a statement Monday, “The vaccine was well tolerated, and the independent data safety monitoring board (DSMB) identified no safety concerns related to the vaccine.”
This should probably come as a surprise to most considering last week over a dozen nations suspended the vaccine after dozens of people began to develop blood clots. Yet in a new review in U.S. trials AstraZeneca has stated that in phase 3 of these trials the vaccine has been “100% effective against severe or critical disease and hospitalization, and 79 percent effective at preventing symptomatic illness.” This review was carried out by none other than the safety monitor board itself.
Another review carried out by The European Union’s drug regulatory agency concluded that, “while it couldn’t rule out a direct link to thrombotic events—or blood clotting—the benefits of using the vaccine outweigh the possible risks.” After this announcement France, Italy, and Germany resumed using the vaccine as of Friday.